Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

Data May Facilitate Closing Of Pfizer Merger

Executive Summary

With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval.

You may also be interested in...

Five Late-Breakers To Look Out For At ESMO

The upcoming European Society for Medical Oncology meeting in Madrid has a full slate of potentially practice-changing late-breaking clinical trials ready to be presented. Here, Scrip takes a look at five of the most eagerly anticipated.

Keytruda Better Than Nothing In Adjuvant Bladder Cancer

Merck’s mega-blockbuster delivers a Phase III hit in muscle-invasive urothelial carcinoma in the adjuvant setting, opening the door for an expanded approval that could ultimately impact ultimately impact revenues at later stages.

Keeping Track: Accelerated Approval Wins (Padcev+Keytruda) And Losses (Imbruvica To Shed MCL, MZL Claims)

The latest drug development news and highlights from the Pink Sheet's US FDA Perfomance Tracker.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts